WO2008146721A1 - 加齢黄斑変性の予防又は治療剤 - Google Patents

加齢黄斑変性の予防又は治療剤 Download PDF

Info

Publication number
WO2008146721A1
WO2008146721A1 PCT/JP2008/059503 JP2008059503W WO2008146721A1 WO 2008146721 A1 WO2008146721 A1 WO 2008146721A1 JP 2008059503 W JP2008059503 W JP 2008059503W WO 2008146721 A1 WO2008146721 A1 WO 2008146721A1
Authority
WO
WIPO (PCT)
Prior art keywords
prophylactic
age
therapeutic agent
macular degeneration
related macular
Prior art date
Application number
PCT/JP2008/059503
Other languages
English (en)
French (fr)
Inventor
Shin-Ichiro Hirai
Atsushi Yoshida
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Priority to CA002686560A priority Critical patent/CA2686560A1/en
Priority to EP08764549A priority patent/EP2163548B1/en
Priority to US12/451,368 priority patent/US8309612B2/en
Priority to CN2008800174326A priority patent/CN101679328B/zh
Priority to AT08764549T priority patent/ATE519756T1/de
Publication of WO2008146721A1 publication Critical patent/WO2008146721A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　本発明は、２－フェニル－１，２－ベンズイソセレナゾール－３（２Ｈ）－オン又はその塩の新たな医薬用途を見出すことを課題とする。２－フェニル－１，２－ベンズイソセレナゾール－３（２Ｈ）－オンまたはその塩は、脈絡膜において優れた血管新生阻害作用を発揮する一方、網膜色素上皮細胞の細胞障害保護作用をも併せ持つので、加齢黄斑変性の予防又は治療剤として有用である。
PCT/JP2008/059503 2007-05-25 2008-05-23 加齢黄斑変性の予防又は治療剤 WO2008146721A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002686560A CA2686560A1 (en) 2007-05-25 2008-05-23 Prophylactic or therapeutic agent for age-related macular degeneration
EP08764549A EP2163548B1 (en) 2007-05-25 2008-05-23 Prophylactic or therapeutic agent for age-related macular degeneration
US12/451,368 US8309612B2 (en) 2007-05-25 2008-05-23 Method for treating age-related macular degeneration
CN2008800174326A CN101679328B (zh) 2007-05-25 2008-05-23 老年黄斑变性的预防或治疗剂
AT08764549T ATE519756T1 (de) 2007-05-25 2008-05-23 Prophylaktikum bzw. therapeutikum für altersbedingte makuladegeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-138519 2007-05-25
JP2007138519 2007-05-25

Publications (1)

Publication Number Publication Date
WO2008146721A1 true WO2008146721A1 (ja) 2008-12-04

Family

ID=40074974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059503 WO2008146721A1 (ja) 2007-05-25 2008-05-23 加齢黄斑変性の予防又は治療剤

Country Status (10)

Country Link
US (1) US8309612B2 (ja)
EP (1) EP2163548B1 (ja)
JP (1) JP5314931B2 (ja)
KR (1) KR20100016140A (ja)
CN (1) CN101679328B (ja)
AT (1) ATE519756T1 (ja)
CA (1) CA2686560A1 (ja)
ES (1) ES2370751T3 (ja)
RU (1) RU2460526C2 (ja)
WO (1) WO2008146721A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107759A1 (ja) * 2008-02-28 2009-09-03 参天製薬株式会社 視神経障害を伴う眼疾患の予防又は治療剤
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3708178T3 (pl) 2009-08-24 2024-05-13 Stealth Biotherapeutics Inc. Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej
EP2493296B1 (en) 2009-10-30 2019-01-09 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
EP3689342A1 (en) * 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
US10154978B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Disorders implicating PUFA oxidation
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
GB201616158D0 (en) 2016-09-22 2016-11-09 Provost Fellows Foundation Scholars & The Other Members Of Board Of The College Of The Holy & Unidv Age-related macular degeneration
US20210220437A1 (en) * 2018-08-02 2021-07-22 Curelab Oncology, Inc. Compositions and Methods Relating to p62 for the Treatment and Prophylaxis of Age-Related Macular Degeneration
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61257412A (ja) 1985-05-09 1986-11-14 Nippon Steel Corp 転炉排ガス処理装置のスカ−トシ−ル装置
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
DE3620674A1 (de) * 1986-06-20 1987-12-23 Nattermann A & Cie Salbe zur behandlung von hauterkrankungen
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
FR2740339B1 (fr) * 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2757860B1 (fr) * 1996-12-27 1999-04-23 Oxis International Sa Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques
JP2001261555A (ja) 2000-03-17 2001-09-26 Dai Ichi Seiyaku Co Ltd 脳動脈中膜肥厚抑制剤
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
JP2006104199A (ja) 2004-09-13 2006-04-20 Santen Pharmaceut Co Ltd 角結膜障害治療剤
ES2389566T3 (es) * 2005-05-17 2012-10-29 Santen Pharmaceutical Co., Ltd. Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
JP5087233B2 (ja) * 2005-05-17 2012-12-05 参天製薬株式会社 角結膜障害の予防または治療剤
CN101959514B (zh) * 2008-02-28 2012-10-31 参天制药株式会社 伴有视神经损伤的眼部疾病的预防或治疗剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOGER S. ET AL.: "Antioxidants may reduce the risk for age-related maculopathy in populations with high ocular exposure to solar radiation", JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, vol. 99, no. 9, SUPPL. 1, 1999, pages A-45, XP004848495 *
BOSCH-MORELL F. ET AL.: "Efficacy of the antioxidant ebselen in experimental uveitis", FREE RADICAL BIOLOGY & MEDICINE, vol. 27, no. 3/4, 1999, pages 388 - 391, XP009133536 *
KHATRI J.J. ET AL.: "Vascular Oxidant Stress Enhances Progression and Angiogenesis of Experimental Atheroma", CIRCULATION, vol. 109, 2004, pages 520 - 525, XP009133535 *
NOWAK J.Z.: "Age-related macular degeneration (AMD): pathogenesis and therapy", PHARMACOLOGICAL THERAPY, vol. 58, 2006, pages 353 - 363, XP002476990 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
US8536207B2 (en) 2005-05-17 2013-09-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
WO2009107759A1 (ja) * 2008-02-28 2009-09-03 参天製薬株式会社 視神経障害を伴う眼疾患の予防又は治療剤

Also Published As

Publication number Publication date
KR20100016140A (ko) 2010-02-12
RU2460526C2 (ru) 2012-09-10
JP5314931B2 (ja) 2013-10-16
CN101679328B (zh) 2011-12-28
CN101679328A (zh) 2010-03-24
EP2163548A4 (en) 2010-06-30
US8309612B2 (en) 2012-11-13
EP2163548B1 (en) 2011-08-10
RU2009148288A (ru) 2011-06-27
US20100120873A1 (en) 2010-05-13
EP2163548A1 (en) 2010-03-17
ES2370751T3 (es) 2011-12-22
JP2009007337A (ja) 2009-01-15
ATE519756T1 (de) 2011-08-15
CA2686560A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2008146721A1 (ja) 加齢黄斑変性の予防又は治療剤
IL246181A0 (en) Methods for the preparation of retinal pigment epithelial cells, preparations containing them and their use for the preparation of drugs for the treatment or prevention of conditions characterized by retinal degeneration
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
WO2012045089A3 (en) Methods for the treatment of allergic diseases
HK1145149A1 (en) Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection
WO2009108730A3 (en) Forms of rifaximin and uses thereof
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2010141796A3 (en) PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
WO2007127273A3 (en) Methods and compositions for altering cell function
UA95105C2 (ru) Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2012047951A3 (en) Human lung stem cells and uses thereof
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
WO2012047525A3 (en) Folate conjugates for treating inflammation of the eye
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880017432.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764549

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20097022899

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2686560

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12451368

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008764549

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009148288

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: JP